Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
33.06
+1.17 (3.65%)
Apr 22, 2025, 12:15 PM EDT - Market open
Bright Minds Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Bright Minds Biosciences stock have an average target of 84.33, with a low estimate of 75 and a high estimate of 93. The average target predicts an increase of 155.12% from the current stock price of 33.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 19, 2025.
Analyst Ratings
The average analyst rating for Bright Minds Biosciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 |
| Buy | 1 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +157.15% | Feb 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $93 | Buy | Initiates | $93 | +181.35% | Jan 23, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $85 | Strong Buy | Initiates | $85 | +157.15% | Jan 10, 2025 |
| Baird | Baird | Buy Initiates $75 | Buy | Initiates | $75 | +126.89% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.